NEOSOMA
Portfolio

Three pillars.
Built from the molecule up.

Neosoma operates across three product domains, each governed by the same scientific standard.

01 — Pillar

Cognitive Performance

Formulations engineered for sustained attention, memory consolidation, neuroplasticity, and stress resilience under cognitive load.

Mechanisms we target
  • ·Acetylcholine modulation
  • ·BDNF expression
  • ·Cerebral blood flow
  • ·Neuroinflammation regulation
  • ·HPA axis modulation
Ingredient categories
  • ·Cholinergics
  • ·Adaptogens
  • ·Peptide precursors
  • ·Nootropic actives
  • ·Mitochondrial cofactors

Our cognitive performance formulations are designed to address these mechanisms through verified, mechanistically justified actives.

02 — Pillar

Longevity & Cellular Health

Compounds and stacks targeting the biological mechanisms of healthy aging — from mitochondrial function to cellular senescence to NAD+ metabolism.

Mechanisms we target
  • ·NAD+ pathway
  • ·Mitochondrial biogenesis
  • ·Autophagy
  • ·Senolytic clearance
  • ·Oxidative stress management
Ingredient categories
  • ·NAD+ precursors
  • ·Senolytics
  • ·AMPK activators
  • ·Mitochondrial actives
  • ·Antioxidant systems

Our longevity & cellular health formulations are designed to address these mechanisms through verified, mechanistically justified actives.

03 — Pillar

Human Performance

Recovery, energy systems, sleep architecture, and resilience for individuals who train hard, work hard, and demand more from their biology.

Mechanisms we target
  • ·ATP regeneration
  • ·Lactate clearance
  • ·Sleep stage optimization
  • ·HRV recovery
  • ·Hormonal regulation
Ingredient categories
  • ·Creatine systems
  • ·Electrolyte engineering
  • ·Sleep actives
  • ·Recovery compounds
  • ·Hormonal support adaptogens

Our human performance formulations are designed to address these mechanisms through verified, mechanistically justified actives.

Forward

What comes next.

Neosoma is building toward fully personalized formulation — products engineered to individual biology rather than archetype. Our long-term roadmap moves from precision archetypes toward fully individualized compounds. We are not yet there. We are building toward it deliberately.